Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

EXTENDED INDICATIONS FOR AVON PATELLO-FEMORAL ARTHROPLASTY



Abstract

Introduction and Aims: Our experience with over 200 cases of Avon patellofemoral replacement (PFR) in the elderly with severe arthritis has been satisfactory, so we have extended the indications to younger patients with severe symptoms and various pathologies.

Method: Sixty-six knees in 53 patients (10M: 46F) under the age of 55 years (average 47 years) have been treated with an AVON PFR for the following conditions:

PATHOLOGY NUMBER of Knees

Isolated lateral facet OA 34

Failed realignment 12

Persistent subluxation/dislocation 5

Trochlear dysplasia 5

Pure chondral disease 3

Failed carbon fibre implant 3

Post-patellectomy instability 3

Post-traumatic pain 1

All patients were recorded prospectively and have been regularly reviewed using the modified Oxford, Bartlett & Bristol Knee scoring systems. The mean follow-up of the group is 24 months.

Results: No patient has been lost to follow-up, all knee scores improved substantially.

Most of the patients retained their range of flexion and the mean range of movement increased from 112 to 122 degrees. Patients with persistent subluxation were the most dramatically improved. There have been no cases of deep infection, loosening or wear.

Conclusion: Avon PFR provides a reliable short-term solution to some of the more difficult and disabling problems of the patello-femoral joint as long as demonstrable pathology is present.

These abstracts were prepared by Editorial Secretary, George Sikorski. Correspondence should be addressed to Australian Orthopaedic Association, Ground Floor, The William Bland Centre, 229 Macquarie Street, Sydney, NSW 2000, Australia.

At least one of the authors is receiving or has received material benefits or support from a commercial source.